Table 3. Drug-resistant distribution of Mycobacterium tuberculosis isolates in different years.
| Drug resistance | TB-HIV coinfection [N (%, 95% CI)] | TB without HIV infection [N (%, 95% CI)] | ||||||
|---|---|---|---|---|---|---|---|---|
| 20141 | 20152 | 2016 3 | 20174 | 20145 | 2015 6 | 2016 7 | 20178 | |
| AFB smear-positive | 9(23.1,9.7~36.5) | 18(34,21.1~46.8) η | 15(33.3,19.4~47.3) η | 10(16.7,7.2~26.2)* | 740(36,33.9~38.1) β,χ | 822(39.6,37.5~41.7) δ | 809(41.3,39.1~43.4) δ | 388(32.9,30.2~35.5) |
| Any drug resistance # | 36(92.3,83.8~100.8)ϕ,γ,η | 30(56.6,43.1~70.1) γ,η | 7(15.6,4.8~26.3) * | 14(23.3,12.5~34.1) | 1752(85.2,83.7~86.7) β,χ,δ | 1147(55.3,53.1~57.4) χ,δ | 605(30.9,28.8~32.9) | 342(29.0,26.4~31.5) |
| Any first-line drug resistance | 14(35.9,20.6~51.1) γ | 15(28.3,16.1~40.5) γ | 3(6.7,-0.7~14) *,η | 13(21.7,11.2~32.2) | 680(33.1,31~35.1) β,χ,δ | 591(28.5,26.5~30.4) | 521(26.6,24.6~28.5) | 308(26.1,23.6~28.6) |
| Any second-line drug resistance | 36(92.3,83.8~100.8) ϕ,γ,η | 30(56.6,43.1~70.1) γ,η | 6(13.3,3.3~23.4) | 8(13.3,4.7~22.0) | 1664(80.9,79.2~82.6) β,χ,δ | 965(46.5,44.4~48.7) χ,δ | 382(19.5,17.7~21.2) δ | 194(16.4,14.3~18.5) |
| INH | 13(33.3,18.3~48.3) γ | 11(20.8,9.7~31.8) γ | 3(6.7,-0.7~14) * | 12(20.0,9.8~30.2) | 544(26.5,24.6~28.4) β,χ,δ | 449(21.6,19.9~23.4) | 453(23.1,21.2~25) | 268(22.7,20.3~25.1) |
| RIF | 8(20.5,7.7~33.4) γ | 11(20.8,9.7~31.8) γ | 2(4.4,-1.6~10.5) | 7(11.7,3.5~19.9) | 443(21.5,19.8~23.3) β,χ,δ | 373(18,16.3~19.6) χ,δ | 271(13.8,12.3~15.3) | 171(14.5,12.5~16.5) |
| STR | 8(20.5,7.7~33.4) γ | 4(7.5,0.4~14.7) | 2(4.4,-1.6~10.5) | 5(8.3,1.3~15.4) | 349(17,15.4~18.6) β,χ,δ | 300(14.5,12.9~16) χ | 232(11.8,10.4~13.3) | 146(12.4,10.5~14.2) |
| EMB | 1(2.6,-2.5~7.6) | 1(1.9,-1.8~5.6) | 0(0,-) | 0(0.0,-) | 50(2.4,1.8~3.1) β,χ | 27(1.3,0.8~1.8) | 23(1.2,0.7~1.6) | 21(1.8,1.0~2.5) |
| OFX | 6(15.4,3.9~26.9) η | 9(17,6.8~27.2) γ,η | 2(4.4,-1.6~10.5) | 2(3.3,-1.2~7.9) | 257(12.5,11.1~13.9) χ,δ | 226(10.9,9.6~12.2) χ | 140(7.1,6~8.3) | 104(8.8,7.2~10.4) |
| LFX | 6(15.4,3.9~26.9) η | 9(17,6.8~27.2) η | 0(0,-) | 1(1.7,-1.6~4.9) | 210(10.2,8.9~11.5) χ,δ | 190(9.2,7.9~10.4) χ,δ | 102(5.2,4.2~6.2) | 68(5.8,4.4~7.1) |
| AMK | 2(5.1,-1.9~12.1) | 4(7.5,0.4~14.7) * | 0(0,-) | 0(0.0,-) | 66(3.2,2.4~4) β,χ,δ | 31(1.5,1~2) χ | 12(0.6,0.3~1) | 13(1.1,0.5~1.7) |
| CM | 3(7.7,-0.8~16.2) * | 1(1.9,-1.8~5.6) | 0(0,-) | 1(1.7,-1.6~4.9) | 24(1.2,0.7~1.6) | 20(1,0.5~1.4) | 13(0.7,0.3~1) | 6(0.5,0.1~0.9) |
| PTO/ETO | 34(87.2,76.5~97.8) ϕ,γ | 23(43.4,29.9~56.9) γ | 1(2.2,-2.1~6.6) | 0(0.0,-) | 1579(76.8,75~78.6) β,χ,δ | 746(36,33.9~38) χ,δ | 63(3.2,2.4~4) δ | 20(1.7,1.0~2.4) |
| MFX | 5(12.8,2.2~23.5) | 9(17,6.8~27.2) η | 5(11.1,1.8~20.4) | 2(3.3,-1.2~7.9) | 220(10.7,9.4~12) δ | 214(10.3,9~11.6) δ | 179(9.1,7.9~10.4) | 96(8.1,6.6~9.7) |
| RFB | 5(12.8,2.2~23.5) | 8(15.1,5.4~24.8) | 2(4.4,-1.6~10.5) | 6(10.0,2.3~17.7) | 290(14.1,12.6~15.6) χ,δ | 255(12.3,10.9~13.7) | 219(11.2,9.8~12.6) | 126(10.7,8.9~12.4) |
| CLR | 0(0.0,-) | 0(0,-) | 1(2.2,-2.1~6.6) | 0(0.0,-) | 37(1.8,1.2~2.4) β,χ | 12(0.6,0.3~0.9) | 14(0.7,0.3~1.1) | 12(1.0,0.4~1.6) |
| pre-XDR | 1(2.6,-2.5~7.6) | 2(3.8,-1.4~9) | 2(4.4,-1.6~10.5) | 2(3.3,-1.2~7.9) | 140(6.8,5.7~7.9) β,χ,δ | 106(5.1,4.2~6.1) | 98(5,4~6) | 51(4.3,3.2~5.5) |
| XDR | 3(7.7,-0.8~16.2) * | 4(7.5,0.4~14.7) * | 0(0,-) | 0(0.0,-) | 45(2.2,1.6~2.8) χ,δ | 33(1.6,1.1~2.1) χ | 8(0.4,0.1~0.7) | 10(0.8,0.3~1.4) |
| MDR (INH+RIF) | 7(17.9,5.7~30.2) | 7(13.2,4~22.4) | 2(4.4,-1.6~10.5) | 7(11.7,3.5~19.9) | 364(17.7,16.1~19.4) β,χ,δ | 302(14.6,13~16.1) χ | 242(12.3,10.9~13.8) | 157(13.3,11.4~15.2) |
| INH+STR | 7(17.9,5.7~30.2) | 4(7.5,0.4~14.7) | 2(4.4,-1.6~10.5) | 4(6.7,0.3~13.0) | 283(13.8,12.3~15.3) β,χ,δ | 224(10.8,9.5~12.1) | 190(9.7,8.4~11) | 120(10.2,8.4~11.9) |
| INH+RIF+STR | 5(12.8,2.2~23.5) | 4(7.5,0.4~14.7) | 2(4.4,-1.6~10.5) | 3(5.0,-0.6~10.6) | 223(10.8,9.5~12.2) β,χ,δ | 176(8.5,7.3~9.7) | 133(6.8,5.7~7.9) | 90(7.6,6.1~9.1) |
| INH+RIF+EMB | 1(2.6,-2.5~7.6) | 1(1.9,-1.8~5.6) | 0(0,-) | 0(0.0,-) | 49(2.4,1.7~3) β,χ | 27(1.3,0.8~1.8) | 19(1,0.5~1.4) | 20(1.7,1.0~2.4) |
| RIF+STR+EMB | 1(2.6,-2.5~7.6) | 1(1.9,-1.8~5.6) | 0(0,-) | 0(0.0,-) | 40(1.9,1.3~2.5) β,χ | 20(1,0.5~1.4) | 15(0.8,0.4~1.2) | 16(1.4,0.7~2.0) |
| INH+RIF+STR+EMB | 5(12.8,2.2~23.5) | 4(7.5,0.4~14.7) | 2(4.4,-1.6~10.5) | 3(5.0,-0.6~10.6) | 233(11.3,10~12.7) β,χ,δ | 183(8.8,7.6~10) | 139(7.1,6~8.2) | 94(8.0,6.4~9.5) |
1n = 39;
2n = 53;
3n = 45;
4n = 60;
5n = 2056;
6n = 2075;
7n = 1961;
8n = 1181.
#: Resistant to at least one drug.
*: P < 0.05 vs. TB without HIV infection group.
α: P < 0.05 vs. 2014 TBw/oHIV group;
β: P < 0.05 vs. 2015 TBw/oHIV group;
χ: P < 0.05 vs. 2016 TBw/oHIV group;
δ: P < 0.05 vs. 2017 TBw/oHIV group.
ε: P < 0.05 vs. 2014 TB-HIV group;
ϕ: P < 0.05 vs. 2015 TB-HIV group;
γ: P < 0.05 vs. 2016 TB-HIV group;
η: P < 0.05 vs. 2017 TB-HIV group.